Vaxcyte ended 2025 with a robust cash balance of $2.4 billion, further bolstered by a $632.5 million equity offering in early 2026. The company is aggressively advancing its pneumococcal conjugate vaccine (PCV) franchise, specifically VAX-31, into Phase 3 trials for adults and Phase 2 for infants, while scaling up manufacturing capabilities with Lonza.

Vaxcyte reported a net loss of $140.7 million for the first quarter of 2025, an increase from the $95.0 million net loss in the same period last year, primarily due to increased R&D and G&A expenses. The company ended the quarter with approximately $3.0 billion in cash, cash equivalents, and investments.

Vaxcyte reported a net loss of $137.1 million for Q4 2024, driven by higher R&D and G&A expenses. The company made significant progress in its clinical programs, including VAX-31 and VAX-24 studies, and raised $2.2 billion in net proceeds from two equity offerings during the year.

Vaxcyte reported positive topline data from Phase 1/2 study of VAX-31 and completed a follow-on equity offering, raising $1.4 billion in net proceeds. VAX-31 was selected to advance to Phase 3 program, with initiation expected by mid-2025. VAX-24 infant Phase 2 study topline data is expected by the end of the first quarter of 2025.

Vaxcyte reported a net loss of $128.7 million for the second quarter of 2024. The company's cash, cash equivalents, and investments totaled $1,851.9 million as of June 30, 2024. Key milestones include the expected topline data from the VAX-31 adult Phase 1/2 study in September 2024 and the advancement of either VAX-24 or VAX-31 to an adult Phase 3 program.

Vaxcyte reported a net loss of $95.0 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $1,899.8 million as of March 31, 2024, including $816.5 million in net proceeds from a February public offering. Enrollment was completed in both the VAX-31 adult Phase 1/2 study and the VAX-24 infant Phase 2 study.

Vaxcyte reported a net loss of $180.8 million for the fourth quarter of 2023. The company's cash, cash equivalents and investments were $1,242.9 million as of December 31, 2023, excluding net proceeds of $816.5 million from a recent public offering. The company also completed enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of IPD in Adults Aged 50 and Older.

Vaxcyte reported $1.4342 billion in cash, cash equivalents and investments as of September 30, 2023. The company's net loss was $92.7 million, compared to $57.9 million for the same period in 2022. VAX-24 adult Phase 3 program is expected to have topline data in 2025. VAX-31 Adult IND Application received FDA Clearance; Phase 1/2 Study Initiation Expected This Quarter and Topline Data Expected in the Second Half of 2024.

Vaxcyte reported a net loss of $68.3 million for the second quarter of 2023. The company's cash, cash equivalents, and investments totaled $1,440.8 million as of June 30, 2023, including $545.3 million in net proceeds from an April public offering. Vaxcyte is advancing its PCV programs and anticipates key milestones, including regulatory interactions for VAX-24 and IND clearance for VAX-31.

Vaxcyte reported positive data from the Phase 2 study in adults aged 65 and older, confirming the clinical potential of VAX-24 and validating the carrier-sparing, cell-free platform. The company's balance sheet was further strengthened by a recent follow-on equity offering, allowing for expansion of manufacturing capabilities and advancement of the PCV franchise.

Vaxcyte reported financial results for Q4 2022, highlighting the FDA clearance of VAX-24 infant IND application, progress of VAX-31, and a strong cash position of $957.9 million, including $651.6 million from a public offering.

Vaxcyte announced positive results from its Phase 1/2 clinical proof-of-concept study, demonstrating VAX-24's potential for broader coverage and better immune responses relative to the standard-of-care. The company's cash, cash equivalents and investments were $366.2 million as of September 30, 2022, excluding net proceeds of approximately $650.7 million from a recent public offering.

Vaxcyte reported cash, cash equivalents and investments of $361.4 million as of June 30, 2022. The company's net loss for the quarter was $48.5 million. Enrollment was completed for the Phase 2 portion of the VAX-24 clinical proof-of-concept study in adults.

Vaxcyte reported cash, cash equivalents and investments of $352.3 million as of March 31, 2022. The company's net loss was $39.0 million for the three months ended March 31, 2022.

Vaxcyte announced its Q4 and full year 2021 financial results, highlighting the completion of VAX-24 drug product manufacturing and the initiation of a Phase 1/2 clinical study for VAX-24. The company's cash, cash equivalents, and investments totaled $273.1 million as of December 31, 2021, excluding net proceeds from a recent public offering.

Vaxcyte reported a net loss of $26.6 million for the third quarter of 2021. The company's cash, cash equivalents and investments were $318.3 million as of September 30, 2021. Vaxcyte expects to submit the VAX-24 IND application to the FDA in the first quarter of 2022.

Vaxcyte reported a net loss of $23.7 million for the second quarter of 2021, with cash, cash equivalents, and investments totaling $341.0 million. The company is advancing its VAX-24 program and received additional funding from CARB-X to advance VAX-A1.

Vaxcyte is advancing its VAX-24 program towards IND submission and has made progress on its pipeline vaccines, VAX-XP and VAX-A1. The company's cash, cash equivalents, and investments totaled $370.9 million as of March 31, 2021.

Vaxcyte reported a net loss of $20.7 million for the fourth quarter of 2020. The company's cash and cash equivalents were $386.2 million as of December 31, 2020, an increase due to Vaxcyte’s IPO in June 2020 and Series D financing in March 2020.

Vaxcyte reported a net loss of $21.0 million for the third quarter ended September 30, 2020. The company's cash and cash equivalents were $397.0 million as of September 30, 2020. Vaxcyte continues to advance its VAX-24 manufacturing activities and pipeline vaccines.

Vaxcyte reported a net loss of $20.3 million for the second quarter of 2020. The company's cash and cash equivalents increased to $410.0 million due to the IPO and Series D financing.